Saruparib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Saruparib
- Molecular weight
- 406.49
- Structure (SMILES)
- CCc1cc2ncc(CN3CCN(c4ccc(C(=O)NC)nc4)CC3)cc2[nH]c1=O
- azd 5305
- Azd 5305
- AZD 5305
- Azd-5305
- AZD-5305
- azd5305
- AZD5305
- saruparib
- Saruparib
- SARUPARIB
- Saruparib (AZD5305)
- saruparib [INN]
- SARUPARIB [USAN]
- Saruparib [WHO-DD]
- saruparib inn
- saruparib usan
- saruparib who dd
- CAS registry numbers
- 2589531-76-8
- ChEMBL ID
- CHEMBL5095220
- InChIKey
- WQAVGRAETZEADU-UHFFFAOYSA-N
- PubChem compound IDs
- 155586901
- FDA ingredient codes (UNII)
- 16MZ1V3RBT
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- saruparib
- Type
- Synthetic organic
- Drug name stem
- -parib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- poly(ADP-ribose) polymerase 1
- Gene symbol
- PARP1
- Protein identifier
- P09874
- Median affinity
- 8.4
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- poly(ADP-ribose) polymerase 2
- Gene symbol
- PARP2
- Protein identifier
- Q9UGN5
- Median affinity
- 5.82
- Affinity units
- pIC50
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000196
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018364
- Highest recorded phase
- 1
- NCT04550104
- NCT05367440
- NCT05573724
- NCT05938270
- NCT06120491
- NCT06380751
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 94.22
- Calculated partition coefficient (ALogP)
- 1.56
- Calculated partition coefficient (XLogP)
- 1.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 30
- Molecular formula
- C22H26N6O2
- Monoisotopic mass
- 406.21172409
- Natural product
- No
- Recorded assays
- 227
- Active assays
- 32
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- 1.9
- Mean
- 1.9
- Minimum
- 1.9
- Maximum
- 1.9
- Unit
- unitless
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 50,000
- Mean
- 50,000
- Minimum
- 50,000
- Maximum
- 50,000
- Unit
- nM
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 99.5
- Mean
- 101
- Minimum
- 73
- Maximum
- 132
- Unit
- %
- Assays
- 4
- Standard deviation
- 30.3425
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 0.02
- Mean
- 0.02
- Minimum
- 0.02
- Maximum
- 0.02
- Unit
- fraction unbound
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Fu
Related records
Trials (18)
- A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
- A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
- AZD5305 hADME in Patients With Advanced Solid Malignancies
- Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
In development for (6)
- Breast cancer Phase 3
- Cancer Phase 2
- Metastatic prostate carcinoma Phase 1
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 1
- Prostate cancer Phase 3